dr. chiara cremolini on frontline folfoxiri plus bevacizumab in mcrc
Published 9 years ago • 1.1K plays • Length 1:10Download video MP4
Download video MP3
Similar videos
-
1:29
dr. cremolini on folfoxiri plus bevacizumab for metastatic colorectal cancer
-
3:58
dr. cathy eng on bevacizumab plus folfoxiri for patients with mcrc
-
4:25
fire-4.5: folfoxiri plus either bevacizumab or cetuximab in mcrc
-
2:45
1l folfoxiri plus cetuximab or bevacizumab for ras wild-type mcrc
-
1:24
fire-4.5: folfoxiri plus either bevacizumab or cetuximab as 1l treatment of braf v600e-mutant mcrc
-
2:59
#esmo21 highlights on atezolizumab combined with folfoxiri bev in 1st-line mcrc: atezotribe study
-
0:51
dr. cremolini on identifying molecular markers in mcrc
-
20:52
understanding follicular lymphoma with dr. patrizia mondello
-
13:32
what is folfox chemotherapy?
-
3:32
colorectal cancer - gabriel charpentier's story
-
3:01
deeper: m-folfoxiri and cetuximab versus bevacizumab in mcrc
-
2:40
folfoxiri plus panitumumab vs mfolfox6/pan for unresectable ras and braf wild-type mcc
-
15:09
folfoxiri bevacizumab atezolizumab versus folfoxiri bevacizumab as first-line treatment of...
-
3:52
dr. chiara cremolini
-
6:20
tribe2: latest data for patients with mcrc
-
1:05
how will the paradigm trial change the mcrc treatment landscape?
-
4:16
fire-3 study: cetuximab versus bevacizumab in metastatic colorectal cancer
-
5:31
should colon cancer treatment depend on tumor location?
-
1:22
influence of sidedness on prognosis and treatment in mcrc
-
8:42
frontline therapy for mcrc
-
1:40
mfolfoxiri/pan vs mfolfox6/pan as initial treatment of patients with unresectable ras & braf wt mcrc
-
4:56
upfront bevacizumab and cetuximab compared in metastatic colorectal cancer